Deals Shaping The Medical Industry, September 2017

 
• By Beth Allan, Deanna Kamienski, Maureen Riordan, Steven Muntner, and Amanda Micklus

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2017.

Dealmaking

Molecular diagnostics firm Cancer Genetics Inc. entered a financing agreement with Aspire Capital, through which Aspire will purchase, over the next two years, up to $16mm of CGI's common stock. Aspire committed to an immediate tranche of $3mm (1mm shares at $3; a 17% discount), and future tranches will be completed at CGI's discretion. The funding will support CGI's concurrent $12mm purchase of Australian CRO vivoPharm Pty. Ltd. (Aug.)

Natera Inc. (genetic testing for reproductive health) entered into a $100mm debt facility with existing investor OrbiMed Advisors. The...

More from Deal-Making

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.